


## Cilobradine hydrochloride

<b>Cat. No.:</b>	HY-18940A
<b>CAS No.:</b>	186097-54-1
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>39</sub> ClN <sub>2</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	519.07
<b>Target:</b>	HCN Channel
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 125 mg/mL (240.82 mM)  
 H<sub>2</sub>O : 100 mg/mL (192.65 mM; Need ultrasonic)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		1.9265 mL	9.6326 mL	19.2652 mL
	5 mM		0.3853 mL	1.9265 mL	3.8530 mL
	10 mM		0.1927 mL	0.9633 mL	1.9265 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Cilobradine is an HCN Channel blocker; an open channel blocker of neuronal Ih and related cardiac If channels. Target: HCN Channel blocker. Cilobradine is a HCN channel blocker that is about 3 times more potent than ZD7288. At a concentration of 10 μM, Cilobradine inhibits WT mHCN2 channel current by 86 ± 2% (n = 5). In contrast, I432A and A425G channel currents were only reduced by 14 ± 1% (n = 4) and 19 ± 2% (n = 8), respectively, by this concentration of Cilobradine. The double mutant (I432A/A425G) channel was even less sensitive to 10 μM Cilobradine (8 ± 2% inhibition; n = 4).

### REFERENCES

[1]. Cheng L, et al. Molecular mapping of the binding site for a blocker of hyperpolarization-activated, cyclic nucleotide-modulated pacemaker channels. J Pharmacol Exp Ther. 2007 Sep;322(3):931-939.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA